ENPP2 Biomarker Detection for Cardiovascular Risk in Viral Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need to determine the risk and severity of cardiovascular disease in subjects with chronic viral infections, such as HIV and HCV, and to develop effective treatment methods for cardiovascular disease associated with these infections, as co-infection with HCV increases the risk of cardiovascular events and metabolic changes induced by antiviral drugs.
Innovation Solution
The method involves determining the levels of ectonucleotide pyrophosphatase/phosphodiesterase-2 (ENPP2) and lysophosphatidic acid (LPA) in subjects, using these biomarkers to assess the risk of cardiovascular disease, and administering ENPP2 inhibitors to treat cardiovascular disease in subjects with increased levels of ENPP2 and/or LPA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If ENPP2 and LPA levels are measured to assess cardiovascular risk in subjects with chronic viral infections, then the accuracy of risk prediction is improved, but the complexity of the diagnostic process increases
Solution Approach 1:
The diagnostic approach is segmented into two distinct measurement components: ENPP2 level determination and LPA level determination. This segmentation allows for systematic assessment of cardiovascular risk through multiple biomarkers while maintaining organized diagnostic procedures. The patent measures these biomarkers separately in biological samples, enabling comprehensive risk evaluation without overwhelming complexity.
Solution Approach 2:
The diagnostic method serves multiple functions simultaneously: it assesses cardiovascular risk, evaluates disease severity, and monitors treatment response in subjects with chronic viral infections. By using ENPP2 and LPA as universal biomarkers that reflect immune activation and cardiovascular risk across different viral infection contexts, the patent creates a multi-functional diagnostic tool that addresses various clinical needs.
2Reliability
If ENPP2 inhibitors are administered to treat cardiovascular disease in subjects with chronic viral infections, then the effectiveness of cardiovascular disease treatment is improved, but the complexity of treatment regimens increases
Solution Approach 1:
ENPP2 inhibitors serve as intermediary substances that block the pathological pathway between chronic viral infection-induced immune activation and cardiovascular disease development. By inhibiting ENPP2, the treatment interrupts the generation of LPA and subsequent pro-inflammatory effects, acting as a mediator that connects immune modulation with cardiovascular protection in infected subjects.
Solution Approach 2:
The treatment approach changes the biochemical parameters within the subject by reducing ENPP2 enzyme activity and consequently lowering LPA levels. This parameter change strategy targets the underlying pathophysiological mechanism linking viral infection to cardiovascular risk, modifying the biochemical environment to prevent or treat cardiovascular disease in infected individuals.
Data Source
AI summary
A method for determining the risk of cardiovascular disease in a subject having a chronic viral infection includes determining a level of ectonucleotide pyrophosphatase/phosphodiesterase-2 (ENPP2) in the subject and comparing the determined level of ENPP2 to a control level, wherein an increased level of ENPP2 is indicative of the subject having an increased risk of cardiovascular disease associated with the chronic viral infection.